|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 SubunitsDepartment of Pharmacology and Toxicology, University of Vienna (S.K., I.B., E.N.T., A.H., S.H.), and Center of Brain Research, Medical University of Vienna, Division of Biochemistry and Molecular Biology (W.S.), Vienna, Austria
GABAA receptors composed of
1,
2,
1 subunits are expressed in only a few areas of the brain and thus represent interesting drug targets. The pharmacological properties of this receptor subtype, however, are largely unknown. In the present study, we expressed
1
2
1-GABAA receptors in Xenopus laevis oocytes and analyzed their modulation by 21 ligands from 12 structural classes making use of the two-microelectrode voltage-clamp method and a fast perfusion system. Modulation of GABA-induced chloride currents (IGABA) was studied at GABA concentrations eliciting 5 to 10% of the maximal response. Triazolam, clotiazepam, midazolam, 2-(4-methoxyphenyl)-2,3,5,6,7,8,9,10-octahydro-cyclohepta-(b)pyrazolo[4,3-d]pyridin-3-one (CGS 20625), 2-(4-chlorophenyl)-pyrazolo[4,3-c]quinolin-3-one (CGS 9896), diazepam, zolpidem, and bretazenil at 1 µM concentrations were able to significantly (>20%) enhance IGABA in
1
2
1 receptors. Methyl-6,7-dimethoxy-4-ethyl-
-carboline-3-carboxylate, 3-methyl-6-[3-trifluoromethyl-phenyl]-1,2,4-triazolo[4,3-b]pyridazine (Cl 218,872), clobazam, flumazenil, 5-(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-3-methyl-[1,2,4]-oxadiazole (Ru 33203), 2-phenyl-4-(3-ethyl-piperidinyl)-quinoline (PK 9084), flurazepam, ethyl-7-methoxy-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c] [1,4]benzodiazepine-1-carboxylate (L-655,708), 2-(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-4-methyl-thiazole (Ru 33356), and 6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)phenylmethanone (Ru 32698) (1 µM each) had no significant effect, and flunitrazepam and 2-phenyl-4-(4-ethyl-piperidinyl)-quinoline (PK 8165) inhibited IGABA. The most potent compounds triazolam, clotiazepam, midazolam, and CGS 20625 were investigated in more detail on
1
2
1 and
1
2
2S receptors. The potency and efficiency of these compounds for modulating IGABA was smaller for
1
2
1 than for
1
2
2S receptors, and their effects on
1
2
1 could not be blocked by flumazenil. CGS 20625 displayed the highest efficiency by enhancing at 100 µM IGABA (
1
2
2) by 775 ± 17% versus 526 ± 14% IGABA (
1
2
1) and 157 ± 17% IGABA (
1
2) (p < 0.05). These data provide new insight into the pharmacological properties of GABAA receptors containing
1 subunits and may aid in the design of specific ligands for this receptor subtype.
Address correspondence to: Dr. Steffen Hering, Department of Pharmacology and Toxicology, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria. E-mail: steffen.hering{at}univie.ac.at
This article has been cited by other articles:
![]() |
R. W. Olsen and W. Sieghart International Union of Pharmacology. LXX. Subtypes of {gamma}-Aminobutyric AcidA Receptors: Classification on the Basis of Subunit Composition, Pharmacology, and Function. Update Pharmacol. Rev., September 1, 2008; 60(3): 243 - 260. [Abstract] [Full Text] [PDF] |
||||